Knowledge Hub

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Pipeline Review, H2 2016

Press Release   •   Jan 23, 2017 05:14 EST

Global Markets Directs, Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Pipeline Review, H2 2016, provides in depth analysis on Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted pipeline therapeutics.

The report provides comprehensive information on the Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics development and features dormant and discontinued projects.

View Report @ http://www.marketresearchreports.biz/analysis/928075

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4)

- The report reviews Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics and enlists all their major and minor projects

- The report assesses Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics

Download Sample Copy Of this Report @ http://www.marketresearchreports.biz/sample/sample/928075

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Content

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) Overview 6

Therapeutics Development 7

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Products under Development by Stage of Development 7

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Products under Development by Therapy Area 8

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Products under Development by Indication 9

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Pipeline Products Glance 10

Early Stage Products 10

Unknown Stage Products 11

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Products under Development by Companies 12

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Products under Development by Universities/Institutes 14

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Therapeutics Assessment 16

Assessment by Monotherapy/Combination Products 16

Assessment by Mechanism of Action 17

Assessment by Route of Administration 19

Assessment by Molecule Type 20

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Companies Involved in Therapeutics Development 21

Addex Therapeutics Ltd 21

Prexton Therapeutics SA 22

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Drug Profiles 23

ADX-88178 - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

JBPOS-0101 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

PXT-2331 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

Small Molecules to Agonize mGluR4 for Parkinson's Disease - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

VU-0418506 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Dormant Projects 30

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Featured News & Press Releases 31

Oct 11, 2016: Addex Initiates New Study in Collaboration with US National Institute of Drug Abuse with ADX88178 in Non-Human Primate Model of Cocaine Addiction 31

Sep 19, 2016: Parkinsons disease: Prexton Therapeutics completes phase 1 clinical trial 31

Jun 13, 2016: Addex mGluR4 Program Demonstrates Potential in Preclinical Models of Neurodegenerative and Psychiatric Diseases 32

 

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.